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Abstract
Background: Penicillinase-producing Neisseria gonorroheae (PPNG) was first isolated in 1976. PPNG strains carrying
blaTEM-1 and blaTEM-135 gene have been described in different countries. Recently, a novel blaTEM-220 allele was detected
in PPNG isolates carrying Toronto/Rio plasmid. The prevalence and characteristics of TEM-220 strains worldwide
are unknown, and therefore, it needs to be studied. The purpose of this study was to detect blaTEM-220 gene in
PPNG strains possessing Toronto/Rio plasmid over a period of ten years in Argentina, and to evaluate the proportion
of isolates producing non-TEM-220 containing the T539C substitution in the blaTEM allele.
Methods: One hundred and fifty one PPNG isolates carrying Toronto/Rio plasmid were studied between 2002 and
2011. A mismatch amplification mutation assay (MAMA) PCR was used to identify the T539C substitution in the blaTEM
allele and a MAMA-PCR protocol was developed to detect the G547A substitution in the blaTEM-220. The reference agar
dilution method of the Clinical and Laboratory Standard Institute (CLSI) was used for susceptibility testing to
five β-lactams antibiotics, ciprofloxacin, tetracycline and azithromycin. In all TEM-220-producing isolates, the whole blaTEM
gene was sequenced and the isolates were typed using N. gonorroheae multiantigen sequence typing (NG-MAST).
Results: MAMA PCR successfully identified the G547A substitution in the blaTEM-220 allele. The proportion of isolates that
possessed the blaTEM-220 allele was 2.6 %, and 93.2 % MAMA TEM-220 PCR-negative isolates showed the T539C
substitution in the blaTEM gene. No differences in the susceptibility to five beta-lactam antibiotics tested were
observed in PPNG isolates TEM-220-producing and PPNG isolates carrying the T539C substitution in the blaTEM
gene. All TEM-220 isolates were indistinguishable by NG-MAST.
Conclusion: This is the first study which shows the prevalence of blaTEM-220 in N. gonorrhoeae isolates carrying
Toronto/Rio plasmid in Argentina. Although the blaTEM-220 allele does not appear to be associated with an extended
spectrum beta-lactamase (ESBL) phenotype of resistance, a single nucleotide polymorphism added to the blaTEM-220 or
blaTEM containing the T539C substitution could lead to the emergence of ESBL. Thus, it is imperative to investigate in
surveillance programs, not only the plasmid type in PPNG isolates and the blaTEM allele associated, but phenotypical
characteristics and geographical distribution of isolates.
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Background
Neisseria gonorrhoeae is the etiological agent of the
sexually transmitted infection gonorrhea, which remains
a major public health issue. It represents 88 million of
the estimated 448 million new cases of curable sexually
transmitted infections that occur globally every year [1].
Over time, N. gonorrhoeae has progressively developed
resistance to a wide range of antibiotics, including peni-
cillin, ciprofloxacin, tetracyclines, macrolides, and more
recently to third-generation cephalosporins [2, 3]. Anti-
microbial resistance in N. gonorrhoeae became apparent
shortly after the introduction of antibiotics into clinical
practice. Moreover, its ability to acquire and/or maintain
antibiotic resistance genes has become a considerable
problem and an obstacle to successful therapeutic
treatment [4, 5]. In 1943, penicillin was introduced as
the first-line treatment of gonorrhea, but it was aban-
doned due to the emergence of chromosomally mediated
penicillin resistance and PPNG isolates [6, 7]. PPNG
strains were reported for the first time in 1976 in the
United Kingdom and the United States [8, 9]. These
strains produce a TEM type β-lactamase, which is car-
ried on several related plasmids. To date, eight plasmid
types have been described and named according to their
epidemiological origin. Strains harbouring Asian, African
and Toronto/Rio plasmids have been reported through-
out the world [10, 11]. Other plasmid variants have been
described, including Nimes, New Zealand, Johannesburg,
and Australian plasmids [12–15]. The PPNG isolate in
Argentina was reported in the 1980’s and has spread
since then [16]. PPNG isolates are highly prevalent in
our country and three plasmids types (Asian, African
and Toronto/Rio plasmids) have been detected, resulting
African and Toronto/Rio the most prevalent.
The first PPNG strains produced a TEM-1 β-lactamase,
a class A enzyme encoded by blaTEM-1 allele [17]. TEM-1
β-lactamase efficiently hydrolyzes penicillins and many
cephalosporins, but it is not an effective catalyst for
extended spectrum cephalosporin turnover. For around
thirty years, other β-lactamases were not described in
gonococci. However, a PPNG isolate carrying a blaTEM-135
gene was reported from Thailand in the year 2009 [18].
TEM-135 was first described in 2005 in a Salmonella
enterica subsp. enterica serovar Typhimurium isolate and
differs from TEM-1 by one single nucleotide substitution
at position 539 (T→C), resulting in a single amino acid
substitution, M182T [19]. Prevalence studies from differ-
ent countries revealed that PPNG isolates possessing
Asian, Toronto/Rio, African and Australian plasmids
carried blaTEM-135 gene [20–23]. Recently PPNG isolates
carrying Toronto/Rio plasmid from Argentina that pos-
sessed the novel blaTEM-220 allele were identified [24].
TEM-220 differs from TEM-135 by one nucleotide substi-
tution at position 547 (G→A), resulting in the amino acid
substitution A185T. The prevalence and characteristics of
TEM-220 strains worldwide are unknown and it seems
imperative to study them.
Prevalence of PPNG isolates in Argentina has been
reported previously, but national data of PPNG isolates
possessing blaTEM-220 is lacking. The objective of our
study was to detect blaTEM-220 gene in PPNG isolates
possessing Toronto/Rio plasmid recovered between 2002
and 2011 in Argentina, and to evaluate the proportion of
isolates producing non-TEM-220 containing the T539C
substitution in the blaTEM allele.
Methods
Collection of isolates
The N. gonorrhoeae clinical isolates investigated in this
study were collected as part of Gonococcal Antimicro-
bial Susceptibility Surveillance Programme-Argentina
(GASSP-AR). The isolates were obtained from 71 med-
ical centers in 24 of the 24 Argentinian provinces from
2002 to 2011. We studied 151 PPNG isolates carrying
Toronto/Rio plasmid previously identified as N. gonor-
rhoeae based on the characteristic colony morphology,
Gram staining, oxidase test, superoxol test (30 %
hydrogen peroxide), carbohydrate utilization test, and
the Phadebact GC Monoclonal Test (MKL Diagnostic
AB, Sollentuna, Sweden) [25]. All isolates were assigned
a code number, preserved in tryptic soy broth (TSB) +
20 % glycerol at – 70 °C and added to the N. gonorrhoeae
isolate collection of the reference laboratory. In this study
only bacterial strains from clinical specimens collected
from GASSP-AR were used and no patient information
was accessed. Consequently, ethical approval was not
required for this study.
Each frozen culture suspension was freshly subcultured
on Difco GC Medium Base agar (BD, Franklin Lakes, NJ,
USA) supplemented with 1 % Britalex enrichment supple-
ment (Britania Lab., Argentina) and incubated at 35 °C in
a humidified environment and enriched with 5 % CO2
during 24 to 48 hours. Cultures were examined once a
day and colonies were subcultured using the same
medium and incubation parameters as above. The identity
of resurrected isolates was confirmed by Gram staining
and the production of beta-lactamase by chromogenic
Nitrocefin disc method (BD, Franklin Lakes, NJ, USA).
Plasmid profile was studied using a boiling plasmid extrac-
tion method followed by agarose gel electrophoresis
detection [26, 27].
Antimicrobial susceptibility testing
The minimal inhibitory concentration (MIC) values of
penicillin, ampicillin, cefuroxime, tetracycline, ciprofloxacin,
ceftriaxone, cefixime and azithromycin were determined
using the reference agar dilution method (CLSI) [28]. The
N. gonorrhoeae ATCC 49226 and WHO reference strains
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were used as quality control for the MIC determinations
[29]. The results were interpreted in accordance with CLSI
breakpoints, except for azithromycin, for which the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) breakpoints were applied [30]. For
ampicillin, as CLSI and EUCAST do not describe any
breakpoints, the susceptibility categories were inferred from
the penicillin breakpoints.
DNA isolation
DNA was extracted from a fresh subculture by the boiling
method. Colonies were suspended in 3 ml of ultrapure
water and adjusted to a turbidity equivalent to a 1
McFarland standard using a calibrated turbidimeter.
An aliquot of 500 μl of this suspension was transferred to
a microcentrifuge tube with a capacity of 1.5 ml, then
heated for 20 min at 98 °C, and cooled to 4 °C for 3 min.
The mixture was centrifuged for 5 min at 10000 rpm and
the supernatant was transferred to a new tube. The
extracted DNA was used directly as template in the PCR
and then stored at −20 °C.
Mismatch amplification mutation assay - PCR
In order to detect N. gonorrhoeae strains possessing
blaTEM-220 allele, a MAMA-PCR protocol was developed
to identify a single nucleotide substitution at position 547
(G→A) in the blaTEM gene. The MAMA TEM-220
primers used in this study were designed using free
online Primer-BLAST (http://www.ncbi.nlm.nih.gov/
tools/primer-blast/). Assay design consisted of a for-
ward primer (T220-F, 5′-TGACACCACGACGCCT
GCTA-3′), which annealed a blaTEM-220 allele-specific
polymorphism, and a conserved reverse primer (T220-R,
5′-ATGATACCGCGAGACCCACG-3′). A ‘destabilizing’
mismatch at the penultimate base position from the 3′end
of the forward primer was introduced to enhance the 3′
mismatch effect (Fig. 1) [31, 32]. Amplification was carried
out in a 25 μl reaction mixture containing 1 μl DNA tem-
plate, 1X reaction buffer, 1.0 mM MgCl2, 0.2 mM (each)
deoxynucleoside triphosphate, 0.5 μM of each primer, and
0.75 unit of Taq polymerase (Invitrogen/Life Technologies,
California, USA). The parameters of the amplification were
as follows: initial denaturation at 96 °C for 2 min, followed
by 30 cycles of 96 °C 10 s, 62 °C for 15 s, and 72 °C for
30 s, with final extension at 72 °C for 2 min in a MyCycler
thermal cycler (Bio-Rad, California, USA). The amplifica-
tion products were analyzed by means of electrophoresis
on a 2 % (w/v) agarose gel. The specificity of the primer
was evaluated by testing the previously described N. gonor-
rhoeae strains: IM4519 and IM4520 containing blaTEM-220,
IM5923 and IM4540 containing blaTEM-135, and IM4629
and IM5257 containing blaTEM-1. These strains were used
as a control in all PCRs.
Detection of the T539C substitution in the blaTEM gene
An allele-specific PCR method previously described was
used to investigate N. gonorrhoeae isolates containing bla-
TEM gene with the substitution at position 539 (T→C)
[33]. N. gonorrhoeae strains IM4540 and IM5923 contain-
ing blaTEM-135 and IM4629 and IM5257 containing
blaTEM-1 were used as controls in the PCR.
Sequencing of the blaTEM-220 isolates
In all isolates that were positive to MAMA TEM-220
PCR, the whole blaTEM was amplified and sequenced to
confirm the blaTEM-220 allele. The blaTEM allele was ampli-
fied as previously described [34]. The PCR products were
purified using AccuPrep® PCR Purification Kit (Bioneer,
Daejeon, Republic of Korea). DNA sequencing was
performed using the BigDye® terminator v3.1 cycle se-
quencing kits (Applied Biosystems, Foster City, CA, USA)
on an ABI 3500 Genetic Analyzer (Applied Biosystems,
Foster City, CA, USA). The sequences were compared
and aligned to previously described blaTEM-220 allele
[GenBank: accession number KM998962] using the
BioEdit (version 7.2.5) software.
Genotyping
The NG-MAST analysis was performed exclusively on
TEM-220-producing isolates. The porB and tbpB alleles
were sequenced, and sequence types (STs) were assigned
at the NG-MAST website (http://www.ng-mast.net)
following the interpretative procedures previously de-
scribed [35].
Fig. 1 Alignment and difference of DNA sequence between the blaTEM-1, blaTEM-135, and blaTEM-220 gene. The nucleotide substitutions found in the
different types of blaTEM alleles are in bold type. The forward primer MAMA TEM-220 used in this study is shown schematically with arrows. Underlined
letter indicates the nucleotide alteration near the 3′ end of the primer to enhance the 3′ mismatch effect
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Results
Over the period from 2002 to 2011, 3895N. gonorrhoeae
isolates were submitted from GASSP-AR for antimicro-
bial susceptibility testing. Overall, 476 (12.2 %) isolates
were β-lactamase positive. The proportion of PPNG
isolates was over 5 % in all years and ranged between 8.9
and 17.9 %. During the period of study two plasmid
types were found. The African plasmid type was the
most common in all years, comprising 325/476 isolates
(68.3 %), followed by Toronto/Rio plasmid 151/476
(31.7 %). The serotyping of N. gonorrhoeae strains carry-
ing Toronto/Rio plasmid revealed that the serogroup
PorB1b (WII/III) predominated among these strains
134/151 (88.7 %), followed by serogroup PorB1a (WI)
17/151 (11.3 %).
Use of the MAMA-PCR protocol for detection of the
G547A substitution
A MAMA-PCR protocol was successfully designed for
the identification of the substitution at position 547
(G→A) in the blaTEM-220 gene. Implementation of the
corresponding PCR protocol showed that the primers
were able to differentiate between PPNG strains with the
G547A mutation in the blaTEM allele and those without
it (Fig. 2).
Four of the 151 PPNG isolates (2.6 %) showed a PCR
product of the expected size (204 bp), suggesting that
these isolates carried the blaTEM-220 gene. PCR amplifi-
cation and sequencing analysis of the whole blaTEM gene
revealed a substitution at position 539 T→C and
547 G→A, confirming that these four isolates possessed
the blaTEM-220 allele.
Identification of the T539C substitution in the blaTEM
gene
The 147/151 MAMA TEM-220 PCR-negative isolates
were investigated for the T539C substitution in the
blaTEM gene. From those, 137/147 (93.2 %) isolates
showed a MAMA TEM-135 PCR product of the
expected size (231 bp), which indicate the presence of
the T539C substitution in the blaTEM gene. The 10/147
(6.8 %) MAMA-TEM135 PCR-negative isolates, were
TEM-1 PCR positive, suggesting the presence of blaTEM-1
allele in these isolates.
MICs of Isolates
The MICs of 137 PPNG isolates carrying the T539C sub-
stitution in the blaTEM gene and all (n = 4) PPNG isolates
carrying blaTEM-220 allele are summarized in Table 1. All
isolates were resistant to penicillin and ampicillin and
susceptible to cefuroxime, cefixime and ceftriaxone. No
differences in MICs of five beta-lactam antibiotics tested
were observed in PPNG isolates producing TEM-220 and
PPNG isolates producing non-TEM-220 carrying the
T539C substitution in the blaTEM gene. The 97.1 % of
PPNG isolates containing the T539C substitution in the
blaTEM gene were susceptible to ciprofloxacin (MIC:
≤0.016 μg/ml), whereas 100 % of PPNG strains producing
TEM-220 were susceptible. All isolates were susceptible
to azithromycin (MIC: ≤ 0.25 μg/ml).
Genotyping
The four PPNG isolates possessing blaTEM-220 were
isolated in 3 of the 24 provinces of Argentina. The
geographic distribution of these isolates was in the north
and southern part of the country. All of this isolates
were indistinguishable by NG-MAST and shared al-
leles por 6406 and tbpB 21, which make up NG-MAST
type 10972.
Discussion
This study was conducted to analyze the prevalence of
blaTEM-220 and to detect the T539C substitution in the
blaTEM allele in PPNG isolates carrying Toronto/Rio
plasmid. Prevalence data on plasmid profile and TEM-type
beta-lactamase of PPNG isolates from South America is
limited [36]. In Argentina, penicillin is not recommended
as first-line therapy for the treatment of gonorrhea since
the early 1990s [37]. However, a high percentage of isolates
are beta-lactamase positive. In this study, the prevalence of
PPNG strains was 12.2 % between 2002 and 2011 and the
plasmid profile revealed two types of circulating plasmids,
resulting the African-type plasmid the most frequent
in all years.
PPNG isolates possessing blaTEM-220 have recently
been described [24]. Here, we describe a MAMA PCR
method for the specific detection of the G547A substitu-
tion in the blaTEM-220 allele. The results showed that the
MAMA PCR successfully detected four PPNG isolates
carrying blaTEM-220, which were confirmed by sequencing
the whole blaTEM gene. The blaTEM-220 allele was found in
2.6 % of all isolates. These strains were resistant to penicil-
lin and ampicillin, but susceptible to cefuroxime, cefixime
Fig. 2 Discrimination of PPNG isolates with the G547A substitution in
blaTEM allele by using T220-f/T220-r primers. Lanes 1 and 2, indicate the
204 bp PCR products from strains IM4519 and IM4520 with the G547A
mutation in blaTEM allele; lanes 3, 4, 5 and 6 indicate PPNG
control strains containing blaTEM-1 and blaTEM-135, respectively,
without amplification; lane M, molecular size marker
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and ceftriaxone. According to this, it is believed that
these substitutions have no effect on the substrate
spectra of the enzyme. Moreover, the β-lactamase
phenotype of blaTEM-220 gene does not correspond to
an ESBL phenotype. All isolates were assigned to
serogroup PorB1b (WII/III) and NG-MAST was used
to investigate the diversity and relatedness of the four
TEM-220-producing isolates. All TEM-220 isolates
were assigned the same ST 10972, indicating that these
strains had originated from a common ancestor. In a
previous study of blaTEM-135 possessing isolates in
Argentina, ST 10972 was found to be prevalent in
19.0 % of the TEM-135 isolates carrying Toronto/Rio
plasmid [24]. We did not observe different patterns of
resistance when comparing susceptibility or resistance
to penicillin, cefixime, ceftriaxone, ciprofloxacin, tetra-
cycline and azithromycin between TEM-220 isolates
and previously described TEM-135 isolates with ST
10972 (data not shown). Based on these observations,
other factor(s) than antimicrobial selective pressure
may have been the selective force that drove the emer-
gence of TEM-220 beta-lactamase. Although blaTEM-220
allele might have been acquired through horizontal gene
transfer from an unknown bacterial source, the highly
similar contexts between TEM-135 and TEM-220 isolates
suggest that blaTEM-220 allele could have evolved from bla-
TEM-135 gene by a single nucleotide polymorphism (SNP).
The study of the substitution at position 539 (T→C) in
MAMA TEM-220 PCR-negative isolates revealed that
93.2 % of the isolates contained this mutation in the bla-
TEM gene. The T539C mutation results in a single amino
acid substitution (M182T), which is believed to restore
the stability of the enzyme affected by substitutions near
the active site [38, 39]. M182T accompanies additional
mutations that may extend the substrate specificity of the
enzyme to ESBL such as TEM-20 and TEM-52 [40, 41].
Nowadays, extended spectrum cephalosporins are used as
first line therapy in our country, and resistance has not
been detected. However, an additional SNP added to the
blaTEM-220 or blaTEM containing M182T substitution
could lead to the emergence of ESBL as a response to the
selective pressure induced by extended spectrum cephalo-
sporin. This leads to the imperative need for monitoring
for the possible emergence and spread of ESBL-producing
N. gonorrhoeae.
A limitation of the current study was the lack of
demographic and epidemiological information which
limited the comparison between PPNG isolates and pa-
tient characteristics.
Conclusions
In summary, this study shows the prevalence of TEM-220
in N. gonorrhoeae isolates carrying Toronto/Rio plasmid in
Argentina. The blaTEM-220 allele does not appear to be as-
sociated with an ESBL phenotype, and high percentage of
PPNG isolates carrying Toronto/Rio plasmid contained the
T539C substitution in the blaTEM gene. Knowledge about
the diversity and prevalence of β-lactamases in PPNG
strains is crucial in order to detect the possible emergence
of resistant variants to extended-spectrum cephalosporin.
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Table 1 Susceptibility of four PPNG isolates producing TEM-220 β-lactamase and PPNG strains containing the T539C substitution in the
blaTEM allele
MIC (μg/ml)
Antimicrobial agent aT539C TEM-220
bMIC50
cMIC90 Isolate 1 Isolate 2 Isolate 3 Isolate 4
Penicillin 64 128 32 64 32 64
Ampicillin 128 256 64 128 128 128
Cefuroxime 0,25 0,5 0,125 0,125 0,125 0,125
Cefixime 0,016 0,016 0,008 0,008 0,008 0,008
Ceftriaxone 0,004 0,008 0,008 0,004 0,008 0,004
Tetracycline 1 4 0,5 1 1 1
Ciprofloxacin 0,004 0,008 0,002 0,004 0,004 0,004
Azithromycin 0,25 0,25 0,25 0,25 0,25 0,25
aNumber of PPNG isolates containing the T539C substitution (n = 137)
bMIC50 : MIC of inhibition of 50 % of strains
cMIC90: MIC of inhibition of 90 % of strains
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